Universal Diagnostics SL
We are developing blood tests that detect cancer in its earliest stages so we can transform cancer into a disease that’s preventable and curable. We are developing Signal-X™, a multi-cancer platform able to detect various types of high-burden cancers with high sensitivity and tissue-of-origin specificity. Since 2012, an international, multi-disciplinary highly experienced team focused on cracking cancer’s code. We have built a network of >100 hospitals in the U.S. and across Europe with whom we have recruited >12K samples and work with more than hundred gastrointestinal clinical teams. We are currently running an observational study, USOPTIVAL, for which we are recruiting 1,200 patients at >15 US hospitals.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical Research
- Market Focus:
- Globally (various continents)
- Year Founded:
- 2012
About us
We are a bioinformatics and multi-omics company. We are driven forward by a vision of a future where cancer is curable.
Global Strategic Partnership
Cancer is too huge of a problem to tackle it alone, so we team up with the best. Our network of world-class R&D partners includes Diagenode -now Hologic (Belgium/U.S.), Polytechnique University of Catalonia (Spain) and Austrian Institute of Technology (Austria). We have built a world-class Scientific Advisory Board from leading oncologist, gastroenterologists, scientists, and business experts from the US and Europe.
Science
We read cancer’s signal
Starting from a deep knowledge of the disease, we have built a technological platform able to “read” the signal of cancer in blood.
What makes our approach unique
1 We started with cancer
We began with extensive tissue, buffy coat and plasma WGBS profiling to discover the most informative markers for individual cancer types.
2 We use a multi-omics approach
Our multi-omics approach combines Methylomics and Fragmentomics to analyze multiple layers of cancer signal and identify pre-cancer and early-stage cancers with high accuracy.
3 We developed state-of-the-art Computational Biology tools
Our tools facilitate extraordinarily accurate marker discovery with the most informative DNA regions.
4 We combine proprietary tools with machine learning algorithms
We combine our proprietary algorithms – AMBER™, which scores cancer signal using read-wise Methylation patterns and CODEdX™, which looks at open chromatin region based for Fragmentation patterns – with machine learning to achieve the highest accuracy in early cancer detection.
5 Our targeted NGS platform achieves high analytical and clinical sensitivity at scale.
A targeted Next Generation Sequencing (NGS) platform reads hundreds of marker regions with high accuracy and fits seamlessly into any clinical lab at economic cost.
Clinical Trials
We are collaborating with leading hospitals, integrated health systems, medical centers and biobanks around the world to conduct studies in order to further develop and validate UDX's blood test for early cancer detection.
+ 100
CLINICAL INSTITUTIONS
6
COUNTRIES
+12 k
SUBJECTS
3
TRIALS
We are currently conducting the USOPTIVAL Study, a prospective multi-center observational study of more than 1,200 eligible subjects from the U.S. to evaluate the performance of UDX's cfDNA marker panel for CRC and advanced adenoma detection.